Lil­ly to build man­u­fac­tur­ing ca­pac­i­ty at risk to pre­pare for next-gen oral obe­si­ty drug

Eli Lil­ly is stuck in a hard place — it’s got the cap­i­tal to spend to boost man­u­fac­tur­ing ca­pac­i­ty. But the com­plex­i­ty of build­ing, buy­ing and get­ting fa­cil­i­ties up and run­ning is a slow process that takes time and tech­ni­cal ex­per­tise.

The drug­mak­er has strug­gled to pro­duce enough of its GLP-1/GIP ag­o­nists even as they gen­er­ate bil­lions of dol­lars in sales. Three dos­es of Moun­jaro, the tirzepatide in­jec­tion ap­proved to treat type 2 di­a­betes, are now in short sup­ply. And Zep­bound, the ver­sion of the drug ap­proved to treat pa­tients who are over­weight or obese, gen­er­at­ed $175 mil­lion in sales in less than a month in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER